Shanghai, China, 26 February 2025 – Shanghai MicroPort Medical (Group) Co., Ltd. is pleased to announce that its Firelimus® Rapamycin Drug-Eluting Balloon Catheter (Firelimus®) has received market approval from the National Medical Products Administration (NMPA) (registration no. 20253030280). This innovative excipient-free drug-coated balloon (DCB) is approved for the treatment of primary coronary bifurcation lesions, offering an advanced alternative to permanent stents.
Firelimus® is designed with rapamycin, a well-established and clinically validated drug known for its superior safety profile. The device incorporates MicroPort®’s proprietary microcrystalline coating technology, ensuring rapid drug transfer to the vessel wall while enabling a sustained, controlled release effect. Unlike traditional drug-coated balloons, Firelimus® eliminates the need for excipients, significantly reducing the risk of vessel inflammation and late thrombosis. With a broad range of specifications, including diameters up to 40mm in length, Firelimus® is engineered to meet diverse clinical needs and expand treatment options for interventional cardiologists.
The approval and market launch of Firelimus® further strengthen MicroPort®’s leadership in coronary intervention. Alongside its next-generation bioresorbable scaffold (BRS), Firesorb®, Firelimus® plays a key role in MicroPort®’s "Intervention Without Implantation" strategy, providing interventional cardiologists with advanced tools for coronary artery interventions and enhanced patient outcomes.
About MicroPort®
Founded in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort® (MicroPort Scientific Corporation; HKEX: 00853) is a global medical technology company. MicroPort® provides solutions across twelve therapeutic areas, including cardiovascular, orthopedics, cardiac rhythm management, electrophysiology, endovascular, neurovascular and surgical robotics among others. For over 27 years, MicroPort® has been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can continue living better and longer lives. With therapeutic solutions that are available in more than 100 countries and over 20,000 hospitals around the world, today, every 5 seconds or less, a patient around the world benefits from a MicroPort® life-changing solution.
More information is available at: www.microport.com.